CCND1 and esophageal squamous cell carcinoma: These findings not only broaden our knowledge on the genetic basis of Gln-addiction, but also provide a way to treat ESCC with cyclin D1 overexpression or Rb loss (Supplementary Fig. 22), and to overcome palbociclib resistance.